OpGen > MDRO Services > Acuitas® MDRO Tests

Acuitas® MDRO Tests

Complete Solution to Control, Confirm, and Combat MDROs
Contact us to order or call Customer Service: (888) 856-2748

 

Acuitas MDRO Gene Test

Identify presence of antibiotic resistant genes for high-risk patients quickly and with high sensitivity and specificity.

Make better informed infection control decisions regarding the need for contact precautions and isolation.

DNA Sequence-based technology detects genes associated with CRE, Carbapenemase Producers, CTX-M related ESBLs, and VRE directly from one swab*.

  • Molecular methods detect more patients at risk than traditional culture.1,2,3,4
  • Coverage of more than 200 sub-types
  • Results delivered from OpGen Clinical Services Laboratory within 24 hours of receipt of specimens
*Validated for peri-anal swabs collected with Eswabs™ (trademark of Copan Diagnostics, Inc). Culture isolates also validated.

 

Acuitas CR Elite Test

Quickly screen for antibiotic resistance genes and confirm the presence of CRE

From one surveillance swab*, test specimens with the Acuitas MDRO Gene Test and phenotypic methods to confirm presence of Carbapenem Resistant Enterobacteriaceae (CRE).

  • Highly sensitive carbapenemase gene detection
  • Isolate obtained from CRE Selective Culture
  • ID/AST confirms organism identity and antibiotic susceptibility profile
  • Receive MDRO Gene Test results from OpGen Clinical Laboratory Services within 24 hours of specimen receipt, get notified of CRE isolate growth within 48 hours, and receive ID/AST reports within 72 hours.
*Validated for peri-anal swabs collected with Eswabs™. Culture isolates also validated.

 

Acuitas Resistome Test

Rapid and comprehensive genotyping of MDRO isolates for epidemiology research and investigations

Genetically characterize susceptible and resistant phenotypes

DNA sequence-based test, detects 49 genes covering over 900 subtypes associated with antibiotic resistance.

  • Detects genes associated with major drug resistance classes: Carbapenemases (including plasmid mediated CRE genes), ESBL, & AmpC
  • For transmission investigations, quickly determines differences among isolates and selects candidates for high resolution Acuitas Whole Genome Sequence Analysis
  • Use Resistome results to create objective , gene-based “digital” profiles of isolates with Acuitas Lighthouse MDRO Management System
  • Analysis available for culture isolates

Detects antibiotic resistance genes associated with organisms such as:

Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae, Citrobacter freundii

Results delivered from OpGen Clinical Services Laboratory within 24 hours of receipt of specimens.

For Research Use Only. Not for use in diagnostic procedures.

Savard et al. The challenges of carbapenemase-producing enterobacteriaceae and infection prevention: protecting patients in the chaos. Infect Control Hosp Epidemiol 2013:34(7).
Schechner et al. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J. Clin. Microbiol. 2009:47(10).
Singh et al.  Rectal screening for Klebsiella pneumoniae carbapenemases: comparison of real-time PCR and culture using two selective screening agar plates. J. Clin. Microbiol 2012:50(8).
Vasoo et al. Rapid and direct real-time detection of blaKPC and blaNDM from surveillance samples .J. Clin. Microbiol 2013:51(11).

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

CLOSE